Skip to main content
. 2020 Jul 6;20(11):e910–e925. doi: 10.1016/j.clml.2020.06.024

Figure 1.

Figure 1

Investigator-assessed Best Overall Responses After Bortezomib-based Induction and After an in-Class Transition (iCT) to IRd (Ixazomib, Lenalidomide, Dexamethasone). ∗Overall Response Rate (ORR) Included Complete Response (CR), Very Good Partial Response (VGPR), and Partial Resonse (PR). †CR Category Included Patients With a CR, Stringent CR, Immunophenotypic CR, or Molecular CR

Abbreviations: CI = confidence interval; MR = minimal response; NE = not evaluable.